demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID 19 hospitalizedCOVID-19 severe or critically
sarilumab CORIMUNO-SARI-1 ... sarilumab Sanofi phase 3 outside US
sarilumab high dose (400mg) Lescure ...
sarilumab low dose (200mg) Lescure ...

5 studies excluded by filtering options 0

4891 sarimulab phase 2 low dose, 0 013selection pending
5333 sarilumab phase 2 high dose, 0 013selection pending
5515 sarilumab Sanofi phase 3 US, 0 110risk of bias not avaialble
5633 ARI-RAF (Della-Torre), 2020 1130not a RCTrisk of bias not avaialble
6465 REMAP-CAP sarilumab, 2021 113high risk of bias